Rucaparib (Rubraca)
Jump to navigation
Jump to search
General information
From the NCI Drug Dictionary: A tricyclic indole poly(ADP-Ribose) polymerase (PARP1) inhibitor with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Rucaparib selectively binds to PARP1 and inhibits PARP1-mediated DNA repair, thereby enhancing the accumulation of DNA strand breaks and promoting genomic instability and apoptosis. This may enhance the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapy and radiation therapy.
Route: PO
Extravasation: n/a
Diseases for which it is used
History of changes in FDA indication
- 12/19/2016: FDA granted accelerated approval "for treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies."
Also known as
CO-338, AG-014699, PF-0136738